Ibrutinib | Annual Sales Report

2024 ACI Convention

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Abbvie

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 5,314

2019 Revenue in Millions : 4,674

Growth (%) : 14

Product Web Link

Corporate PDF

02 Brand Name : Imbruvica

2024 ACI Convention

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AbbVie

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 5,408

2020 Revenue in Millions : 5,314

Growth (%) : 2

Product Web Link

Corporate PDF

03 Brand Name : Imbruvica

2024 ACI Convention

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AbbVie

Ibrutinib

Main Therapeutic Indication : Chronic lymphocytic leukemia

Currency : USD

2015 Revenue in Millions : 0

2014 Revenue in Millions : 754

Growth (%) : New Launch

Product Web Link

Corporate PDF

04 Brand Name : Imbruvica

2024 ACI Convention

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AbbVie

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 4,568

2021 Revenue in Millions : 5,408

Growth (%) : -16

Product Web Link

Corporate PDF

05 Brand Name : Imbruvica

2024 ACI Convention

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AbbVie

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 3,596

2022 Revenue in Millions : 4,568

Growth (%) : -21

Product Web Link

Corporate PDF

06 Brand Name : Imbruvica

2024 ACI Convention

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Abbvie

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 2,573

2016 Revenue in Millions : 1,832

Growth (%) : 40

Product Web Link

Corporate PDF

07 Brand Name : Imbruvica

2024 ACI Convention

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Abbvie

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 1,832

2015 Revenue in Millions : 754

Growth (%) : 143

Product Web Link

Corporate PDF

08 Brand Name : Imbruvica

2024 ACI Convention

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Abbvie

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 3,590

2017 Revenue in Millions : 2,573

Growth (%) : 40%

Product Web Link

Corporate PDF

09 Brand Name : Imbruvica

2024 ACI Convention

Not Confirmed

U.S.A